David A. Claassen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David A. Claassen has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Angie Rizzino
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA
2 shared publications Amanda Helip‐Wooley
Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute
1 shared publicationBrian Boer
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198-6805, USA
1 shared publicationGregory M. Cooper
HudsonAlpha Institute for Biotechnology, Huntsville, Alabama 35806, USA
1 shared publicationHeidi Dorward
Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute
1 shared publicationJames G. White
Department of Laboratory Medicine, University of Minnesota, Minneapolis, MN, USA
1 shared publication
Latest Publications
- Open Access
- 17 December 2018
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 4 (6) , a003384
Complexities of genetic diagnosis illustrated by an atypical case of congenital hypoplastic anemia
Diamond–Blackfan Anemia (DBA) is a rare polygenic disorder defined by congenital hypoplastic anemia with marked decrease or absence of bone marrow erythroid precursors. Identifying the specific genetic etiology is important for counseling and clinical management. A 6-yr-old boy with a clinical diagnosis of DBA has been followed by our pediatric hematology team since birth. His clinical course includes transfusion-dependent hypoplastic anemia and progressive autoimmune cytopenias. Genetic testing failed to identify a causative mutation in any of the classical DBA-associated genes. He and his parents underwent trio whole-exome sequencing (WES) with no genetic etiology identified initially. Clinical persistence and suspicion led to testing for adenosine deaminase 2 (ADA2) activity and whole-genome sequencing (WGS) that identified compound heterozygous pathogenic mutations in the ADA2-encoding CECR1 gene, a recently appreciated etiology for congenital hypoplastic anemia. This case illustrates current challenges in genetic testing and how they can be overcome by multidisciplinary expertise in clinical medicine and genomics.
- 17 December 2018
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 4 (6) , a003384
Open AccessComplexities of genetic diagnosis illustrated by an atypical case of congenital hypoplastic anemia
Diamond–Blackfan Anemia (DBA) is a rare polygenic disorder defined by congenital hypoplastic anemia with marked decrease or absence of bone marrow erythroid precursors. Identifying the specific genetic etiology is important for counseling and clinical management. A 6-yr-old boy with a clinical diagnosis of DBA has been followed by our pediatric hematology team since birth. His clinical course includes transfusion-dependent hypoplastic anemia and progressive autoimmune cytopenias. Genetic testing failed to identify a causative mutation in any of the classical DBA-associated genes. He and his parents underwent trio whole-exome sequencing (WES) with no genetic etiology identified initially. Clinical persistence and suspicion led to testing for adenosine deaminase 2 (ADA2) activity and whole-genome sequencing (WGS) that identified compound heterozygous pathogenic mutations in the ADA2-encoding CECR1 gene, a recently appreciated etiology for congenital hypoplastic anemia. This case illustrates current challenges in genetic testing and how they can be overcome by multidisciplinary expertise in clinical medicine and genomics.
- 8 June 2009
- Published by Wiley in Molecular Reproduction and Development
- Vol. 76 (8) , 722-732
ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells
Poor recovery of cryopreserved human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells is a significant impediment to progress with pluripotent stem cells. In this study, we demonstrate that Y‐27632, a specific inhibitor of Rho kinase (ROCK) activity, significantly enhances recovery of hES cells from cryopreserved stocks when cultured with or without a growth inactivated feeder layer. Furthermore, treatment with the ROCK inhibitor for several days increased the number of colonies and colony size of hES cells compared to shorter exposures. Remarkably, hES cells that had formed relatively few colonies 5 days after thawing exhibited rapid growth upon addition of Y‐27632. Additionally, we determined that Y‐27632 significantly improves the recovery of cryopreserved human iPS cells and their growth upon subculture. Thus, Y‐27632 provides a means to “kick‐start” slow‐growing human pluripotent stem cells, especially after being thawed from frozen stocks. Together, these results argue that Y‐27632 is a useful tool in overcoming obstacles to studies involving the cultivation of both hES cells and human iPS cells. Mol. Reprod. Dev. 76: 722–732, 2009.
- 8 June 2009
- Published by Wiley in Molecular Reproduction and Development
- Vol. 76 (8) , 722-732
ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells
Poor recovery of cryopreserved human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells is a significant impediment to progress with pluripotent stem cells. In this study, we demonstrate that Y‐27632, a specific inhibitor of Rho kinase (ROCK) activity, significantly enhances recovery of hES cells from cryopreserved stocks when cultured with or without a growth inactivated feeder layer. Furthermore, treatment with the ROCK inhibitor for several days increased the number of colonies and colony size of hES cells compared to shorter exposures. Remarkably, hES cells that had formed relatively few colonies 5 days after thawing exhibited rapid growth upon addition of Y‐27632. Additionally, we determined that Y‐27632 significantly improves the recovery of cryopreserved human iPS cells and their growth upon subculture. Thus, Y‐27632 provides a means to “kick‐start” slow‐growing human pluripotent stem cells, especially after being thawed from frozen stocks. Together, these results argue that Y‐27632 is a useful tool in overcoming obstacles to studies involving the cultivation of both hES cells and human iPS cells. Mol. Reprod. Dev. 76: 722–732, 2009.
- 6 June 2008
- Published by Wiley in Molecular Reproduction and Development
- Vol. 76 (2) , 173-182
Regulation of the Nanog gene by both positive and negativecis-regulatory elements in embryonal carcinoma cells and embryonic stem cells
The transcription factor Nanog is essential for mammalian embryogenesis, as well as the pluripotency of embryonic stem (ES) cells. Work with ES cells and embryonal carcinoma (EC) cells previously identified positive and negative cis‐regulatory elements that influence the activity of the Nanog promoter, including adjacent cis‐regulatory elements that bind Sox2 and Oct‐3/4. Given the importance of Nanog during mammalian development, we examined the cis‐regulatory elements required for Nanog promoter activity more closely. In this study, we demonstrate that two positive cis‐regulatory elements previously shown to be active in F9 EC cells are also active in ES cells. We also identify a novel negative regulatory region that is located in close proximity to two other positive Nanog cis‐regulatory elements. Although this negative regulatory region is active in F9 EC cells and ES cells, it is inactive in P19 EC cells. Furthermore, we demonstrate that one of the positive cis‐regulatory elements active in F9 EC cells and ES cells is inactive in P19 EC cells. Together, these and other studies suggest that Nanog transcription is regulated by the interplay of positive and negative cis‐regulatory elements. Given that P19 appears to be more closely related to a later developmental stage of mammalian development than F9 and ES cells, differential utilization of cis‐regulatory elements may reflect mechanisms used during development to achieve the correct level of Nanog expression as embryogenesis unfolds. Mol. Reprod. Dev. 76: 173–182, 2009.
- 6 June 2008
- Published by Wiley in Molecular Reproduction and Development
- Vol. 76 (2) , 173-182
Regulation of the Nanog gene by both positive and negativecis-regulatory elements in embryonal carcinoma cells and embryonic stem cells
The transcription factor Nanog is essential for mammalian embryogenesis, as well as the pluripotency of embryonic stem (ES) cells. Work with ES cells and embryonal carcinoma (EC) cells previously identified positive and negative cis‐regulatory elements that influence the activity of the Nanog promoter, including adjacent cis‐regulatory elements that bind Sox2 and Oct‐3/4. Given the importance of Nanog during mammalian development, we examined the cis‐regulatory elements required for Nanog promoter activity more closely. In this study, we demonstrate that two positive cis‐regulatory elements previously shown to be active in F9 EC cells are also active in ES cells. We also identify a novel negative regulatory region that is located in close proximity to two other positive Nanog cis‐regulatory elements. Although this negative regulatory region is active in F9 EC cells and ES cells, it is inactive in P19 EC cells. Furthermore, we demonstrate that one of the positive cis‐regulatory elements active in F9 EC cells and ES cells is inactive in P19 EC cells. Together, these and other studies suggest that Nanog transcription is regulated by the interplay of positive and negative cis‐regulatory elements. Given that P19 appears to be more closely related to a later developmental stage of mammalian development than F9 and ES cells, differential utilization of cis‐regulatory elements may reflect mechanisms used during development to achieve the correct level of Nanog expression as embryogenesis unfolds. Mol. Reprod. Dev. 76: 173–182, 2009.
- Open Access
- 12 September 2007
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 16 (24) , 3088-3096
Expansions of CAG{middle dot}CTG repeats in immortalized human astrocytes
Expansions of trinucleotide repeats (TNRs) are the genetic cause for a number of neurodegenerative disorders. In some of these diseases, ongoing somatic expansions in the brain are thought to contribute to disease progression. Expansions can occur in both neurons and supporting glial cells, but little is known about molecular mechanisms of expansion in these cells, particularly glia. To help address this issue, a cultured human astrocyte cell line called SVG-A was tested for expansions of CAG•CTG repeats present on a shuttle vector. A quantitative genetic selection showed that +4 to +15 repeat expansions occur readily for starting alleles of 25 repeats, thereby spanning the important boundary between short stable repeats and longer more unstable CAG•CTG tracts. These expansions in glial cell culture, as in humans, were sequence and length-dependent, and were inhibited by the presence of a sequence interruption within the triplet repeat tract. These findings suggest that the mutations seen in cell culture reflect at least some of the in vivo expansions seen in glia. Mechanistically, it was found that the direction of DNA replication through the TNR influenced the frequency of expansions, suggesting that either replication or a replication-associated process, such as DNA repair, contributes to CAG•CTG tract instability in SVG-A cells. This finding is consistent with the idea that replication-based mechanisms can be a source of TNR expansions in astrocytes, which, unlike neurons, retain proliferative capacity throughout life.
- 12 September 2007
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 16 (24) , 3088-3096
Open AccessExpansions of CAG{middle dot}CTG repeats in immortalized human astrocytes
Expansions of trinucleotide repeats (TNRs) are the genetic cause for a number of neurodegenerative disorders. In some of these diseases, ongoing somatic expansions in the brain are thought to contribute to disease progression. Expansions can occur in both neurons and supporting glial cells, but little is known about molecular mechanisms of expansion in these cells, particularly glia. To help address this issue, a cultured human astrocyte cell line called SVG-A was tested for expansions of CAG•CTG repeats present on a shuttle vector. A quantitative genetic selection showed that +4 to +15 repeat expansions occur readily for starting alleles of 25 repeats, thereby spanning the important boundary between short stable repeats and longer more unstable CAG•CTG tracts. These expansions in glial cell culture, as in humans, were sequence and length-dependent, and were inhibited by the presence of a sequence interruption within the triplet repeat tract. These findings suggest that the mutations seen in cell culture reflect at least some of the in vivo expansions seen in glia. Mechanistically, it was found that the direction of DNA replication through the TNR influenced the frequency of expansions, suggesting that either replication or a replication-associated process, such as DNA repair, contributes to CAG•CTG tract instability in SVG-A cells. This finding is consistent with the idea that replication-based mechanisms can be a source of TNR expansions in astrocytes, which, unlike neurons, retain proliferative capacity throughout life.
- Open Access
Cellular, Molecular and Clinical Characterization of Patients with Hermansky–Pudlak Syndrome Type 5
Hermansky–Pudlak syndrome (HPS) is a disorder of lysosome‐related organelles such as melanosomes and platelet dense granules. Seven genes are now associated with HPS in humans. An accurate diagnosis of each HPS subtype has important prognostic and treatment implications. Here we describe the cellular, molecular, and clinical aspects of the recently identified HPS‐5 subtype. We first analyzed the genomic organization and the RNA expression pattern ofHPS5, located on chromosome 11p14, and demonstrated tissue‐specific expression of at least three alternatively splicedHPS5mRNA transcripts, coding for HPS5A and HPS5B proteins, that differ at their 5′‐ends. Genetic screening of 15 unassigned HPS patients yielded six newHPS5mutations in four patients. Clinically, our HPS‐5 patients exhibited iris transillumination, variable hair and skin pigmentation, and absent platelet dense bodies, but not pulmonary fibrosis or granulomatous colitis. In two patients with homozygous missense mutations, hemizygosity was ruled out by gene‐dosage multiplex polymerase chain reaction, and immunocytochemical analyses of their fibroblasts supported the HPS‐5 diagnosis. Specifically, LAMP‐3 distribution was restricted to the perinuclear region in HPS‐5 fibroblasts, in contrast to the normal LAMP‐3 distribution, which extended to the periphery. This specific intracellular vesicle distribution in fibroblasts, in combination with the clinical features, will improve the characterization of the HPS‐5 subtype.
Open AccessCellular, Molecular and Clinical Characterization of Patients with Hermansky–Pudlak Syndrome Type 5
Hermansky–Pudlak syndrome (HPS) is a disorder of lysosome‐related organelles such as melanosomes and platelet dense granules. Seven genes are now associated with HPS in humans. An accurate diagnosis of each HPS subtype has important prognostic and treatment implications. Here we describe the cellular, molecular, and clinical aspects of the recently identified HPS‐5 subtype. We first analyzed the genomic organization and the RNA expression pattern ofHPS5, located on chromosome 11p14, and demonstrated tissue‐specific expression of at least three alternatively splicedHPS5mRNA transcripts, coding for HPS5A and HPS5B proteins, that differ at their 5′‐ends. Genetic screening of 15 unassigned HPS patients yielded six newHPS5mutations in four patients. Clinically, our HPS‐5 patients exhibited iris transillumination, variable hair and skin pigmentation, and absent platelet dense bodies, but not pulmonary fibrosis or granulomatous colitis. In two patients with homozygous missense mutations, hemizygosity was ruled out by gene‐dosage multiplex polymerase chain reaction, and immunocytochemical analyses of their fibroblasts supported the HPS‐5 diagnosis. Specifically, LAMP‐3 distribution was restricted to the perinuclear region in HPS‐5 fibroblasts, in contrast to the normal LAMP‐3 distribution, which extended to the periphery. This specific intracellular vesicle distribution in fibroblasts, in combination with the clinical features, will improve the characterization of the HPS‐5 subtype.
- 27 March 2003
- Published by Springer Nature in Human Genetics
- Vol. 113 (1) , 10-17
Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics
Hermansky-Pudlak syndrome (HPS) is an autosomal recessive disorder of oculocutaneous albinism and bleeding attributable to storage-pool-deficient platelets. Although at least 14 mouse models of HPS exist, the human disorders that comprise HPS, i.e., HPS-1, HPS-2, HPS-3, and HPS-4, are recognized to result from mutations in four genes, viz., HPS1, ADTB3A, HPS3, and HPS4, respectively. To characterize further the recently identified HPS-4 disease on molecular and clinical grounds, we first identified the genomic organization of HPS4, located on chromosome 22q11.2–q12.2, including its intron/exon boundaries. We found that HPS4 produces at least two alternatively spliced mRNA transcripts that differ at their 5'-ends. Next, we performed an extensive analysis of 22 unassigned HPS patients (i.e., not having HPS-1, HPS-2, or HPS-3 disease). Using single-strand conformation polymorphism, we determined that seven of the 22 patients had HPS-4. In these seven individuals, we identified five different HPS4 mutations, including one frameshift insertion, one missense, and three nonsense mutations. Three alleles in two patients contained the previously reported Q698insAAGCA frameshift. Three HPS4 mutations were newly described. Four alleles in three patients contained R217X, and two siblings were compound heterozygotes for E138X and E222X. Clinically, our HPS-4 patients exhibited iris transillumination, variable hair and skin pigmentation, absent platelet dense bodies, and occasional pulmonary fibrosis and granulomatous colitis, a severe phenotype similar to that of patients with HPS-1.
- 27 March 2003
- Published by Springer Nature in Human Genetics
- Vol. 113 (1) , 10-17
Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics
Hermansky-Pudlak syndrome (HPS) is an autosomal recessive disorder of oculocutaneous albinism and bleeding attributable to storage-pool-deficient platelets. Although at least 14 mouse models of HPS exist, the human disorders that comprise HPS, i.e., HPS-1, HPS-2, HPS-3, and HPS-4, are recognized to result from mutations in four genes, viz., HPS1, ADTB3A, HPS3, and HPS4, respectively. To characterize further the recently identified HPS-4 disease on molecular and clinical grounds, we first identified the genomic organization of HPS4, located on chromosome 22q11.2–q12.2, including its intron/exon boundaries. We found that HPS4 produces at least two alternatively spliced mRNA transcripts that differ at their 5'-ends. Next, we performed an extensive analysis of 22 unassigned HPS patients (i.e., not having HPS-1, HPS-2, or HPS-3 disease). Using single-strand conformation polymorphism, we determined that seven of the 22 patients had HPS-4. In these seven individuals, we identified five different HPS4 mutations, including one frameshift insertion, one missense, and three nonsense mutations. Three alleles in two patients contained the previously reported Q698insAAGCA frameshift. Three HPS4 mutations were newly described. Four alleles in three patients contained R217X, and two siblings were compound heterozygotes for E138X and E222X. Clinically, our HPS-4 patients exhibited iris transillumination, variable hair and skin pigmentation, absent platelet dense bodies, and occasional pulmonary fibrosis and granulomatous colitis, a severe phenotype similar to that of patients with HPS-1.